Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will … – Benzinga

Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will
Benzinga
The findings from the Pharmacor topic entitled Asthma reveal that Relovair will emerge as the market leader among once-daily LABA/ICS combinations as GlaxoSmithKline wages an aggressive campaign to switch patients off of Advair/Seretide/Adoair prior to

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.